Ascendis Pharma and Royalty Pharma enter into USD 150 million royalty funding agreement

Mazanti-Andersen advises long-term client Ascendis Pharma A/S, a biopharmaceutical company that utilises its innovative TransCon™ technologies to address unmet medical needs, in connection with a royalty agreement with Royalty Pharma, a leading funder of innovation across the biopharma industry.

Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a USD 150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of YORVIPATH. YORVIPATH is the first and only FDA approved treatment of hypoparathyroidism in adults.

Under the terms of the agreement, Ascendis receives an upfront payment of USD 150 million in exchange for a 3% royalty on U.S. net sales of YORVIPATH.

Mazanti Transactions acted as Danish legal counsel to long term client Ascendis Pharma with a team comprising Lars Lüthjohan and Gyrithe Falck.